Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products. It offers endocrinology products for the treatment of diabetes, osteoporosis in postmenopausal women and men, and human growth hormone deficiency and pediatric growth conditions. The Company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, schizophrenia, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and more.

HQIndianapolis, US
Size (employees)40,655 (est)-3%
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Eli Lilly

David A. Ricks

David A. Ricks

Chairman and Chief Executive Officer
Melissa Stapleton Barnes

Melissa Stapleton Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique A. Conterno

Enrique A. Conterno

Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen F. Fry

Stephen F. Fry

Senior Vice President, Human Resources and Diversity
Michael J. Harrington

Michael J. Harrington

Senior Vice President and General Counsel
Johna L. Norton

Johna L. Norton

Senior Vice President, Global Quality
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Puebla, Monterrey, Toluca, Cuernavaca and in 141 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Show all (196)
Report incorrect company information

Eli Lilly Financials and Metrics

Eli Lilly Revenue

Embed Graph
Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.

Market capitalization (15-Oct-2018)


Closing stock price (15-Oct-2018)

Eli Lilly's current market capitalization is $118.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016



Revenue growth, %


Cost of goods sold


Gross profit

USDQ1, 2018



Pre tax profit

USDFY, 2013FY, 2014FY, 2015FY, 2016



Accounts Receivable




Current Assets

USDQ1, 2018

Current Liabilities


Additional Paid-in Capital

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income


Cash From Operating Activities


Purchases of PP&E


Cash From Investing Activities

USDQ2, 2018

Depreciation and Amortization


Cash From Operating Activities

Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AurKa PharmaMay 15, 2018$575 m
ARMO BioSciences IncMay 11, 2018$1.60 b
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.40 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.50 b
Report incorrect company information

Eli Lilly Online and Social Media Presence

Embed Graph
Report incorrect company information

Eli Lilly News and Updates

Diabetes Management Market 2018 Global Analysis By Key Players – Abbott, Bayer, Bristol-Myers Squibb, Eli Lilly, Sanofi, Dexcom

WiseGuyReports.Com Publish a New Market Research Report On –“ Diabetes Management Market 2018 Global Analysis By Key Players – Abbott, Bayer, Bristol-Myers Squibb, Eli Lilly, Sanofi, Dexcom”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Biologics 2018 Global Market Key Players – Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion – Analysis and Forecast to 2023

WiseGuyRerports.com Presents “Global Biologics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Pain Management Drugs 2018-2025 Pfizer, GSK, Grunenthal, Bayer, Sanofi, Eli Lilly, AstraZeneca, Endo, Merck, Depomed, Yunnan Baiyao, Teva, J&J, Allergan, Purdue

Latest Report Available at Analytical Research Cognizance ,Pain Management Drugs Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth. Posted via Industry Today. Follow us on Twitter @Indust…

Eli Lilly enters autoimmune segment in India with launch of Olumiant

Drug firm Eli Lilly and Company Thursday said it has entered the autoimmune segment in India with launch of Olumiant, a new once-daily oral therapy for treatment of rheumatoid arthritis. Olumiant is approved in more than 50 countries across the world, it said. "Lilly India is excited to announce the…

Eli Lilly plans expansion, looks to grow presence in Indian market

Eli plans to bring some of its molecules from the global pipeline to India, especially in the oncology and diabetes space

Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial shows positive results (LLY)

On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company's stock rose 3% on the news.  The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.  The late-stage…
Show more
Report incorrect company information

Eli Lilly Company Life and Culture

Report incorrect company information